Abstract
Osteoarthritis in horses and in humans is a significant social and economic problem and continued research and improvements in therapy are needed. Because horses have naturally occurring osteoarthritis, which is similar to that of humans, the horse was chosen as a species with which to investigate gene transfer as a potential therapeutic modality for the clinical treatment of osteoarthritis. Using an established model of equine osteoarthritis that mimics clinical osteoarthritis, the therapeutic effects resulting from intra-articular overexpression of the equine interleukin-1 receptor antagonist gene through adenoviral-mediated gene transfer were investigated. In vivo delivery of the equine IL-IRa gene led to elevated intra-articular expression of interleukin-1 receptor antagonist for approximately 28 days, resulting in significant improvement in clinical parameters of pain and disease activity, preservation of articular cartilage, and beneficial effects on the histologic parameters of synovial membrane and articular cartilage. Based on these findings, gene transfer of interleukin-1 receptor antagonist is an attractive treatment modality for the equine patient and also offers future promise for human patients with osteoarthritis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Evans C.H., Robbins P.D. . Gene therapy for arthritis Wolff JA (eds); Gene Therapeutics: Methods and Applications of Direct Gene Transferm Birkhauser 1994 pp 320–343
Evans C.H. et al. Clinical trials in the gene therapy of arthritis Clin Orthop 2000 379: 300 300
Auer J., Fackelman G. . Treatment of degenerative joint disease of the horse a review and commentary Vet Sur 1981 2: 80 80
Vachon A., McIlwraith C.W. . Articular cartilage healing: Current concepts White NA, Moore JN (eds); Current Practice of Equine Surgery Lippincott 1990 pp 539–645
Frisbie D.D. et al. The effects of 6-alpha methylprednisolone acetate on an in vivo equine osteochondral fragment exercise model Am J Vet Res 1998 12: 1619 1619
McIlwraith C.W. . General pathobiology of the joint and response to injury McIlwraith CW, Trotter GW (eds); Joint Disease in the Horse WB Saunders Company 1997 pp 40–70
Evans C.H. et al. Gene therapy for rheumatic diseases Arthritis Rheum 1999 42: 1 1
Evans C.H., Robbins P.D. . Potential treatment of osteoarthritis by gene therapy Rheum Dis Clin North Am 1999 25: 333 333
Muzzonigro T.S. et al. The role of gene therapy. Fact or fiction? Clin Sports Med 1999 18: 223 223
Evans C.H., Robbins P.D. . Gene therapy of arthritis Intern Med 1999 38: 233 233
Howard R.D. et al. Cloning of equine interleukin 1 receptor antagonist and determination of its full-length cDNA sequence Am J Vet Res 1998 9: 712 712
Howard R.D. et al. Cloning of equine interleukin 1 receptor antagonist and determination of its full-length cDNA sequence
Takafuji VA, McIlwraith CW, Howard RD. Effects of recombinant equine interleukin-1alpha and interleukin-1beta on proteoglycan metabolism and prostaglandin E2 synthesis in equine articular cartilage explants. Am J Vet Res 2001 (accepted) Am J Vet Res 2000 61: 436 436
Roessler B.J. et al. Inhibition of interleukin-1 induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector Hum Gene Ther 1995 6: 307 307
Bandara G. et al. Intraarticular expression of biologically active interleukin-1 receptor antagonist protein by ex vivo gene transfer Proc Nat Acad Sci USA 1993 90: 10764 10764
Hung G. et al. Suppression of the intraarticular response to interleukin-1 by transfer of the interleukin-1 receptor antagonists gene to synovium Gene Therapy 1994 1: 64 64
Pelletier J.P. et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy Arthritis Rheum 1997 40: 1012 1012
Muller-Ladner U. et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective J Immunol 1997 158: 3492 3492
Otani K. et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy J Immunol 1996 156: 3558 3558
Roessler B.J. et al. Adenoviral-mediated gene transfer to rabbit synovium in vivo J Clin Invest 1993 92: 1085 1085
Arend W.P. et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist J Clin Invest 1990 85: 1694 1694
Smith R.J. et al. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1 stimulated cartilage erosion and chondrocyte responsiveness Arthritis Rheum 1991 34: 78 78
Henderson B. et al. Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human, interleukin-1-receptor antagonist Cytokine 1991 3: 246 246
Van Lent P.L. et al. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice J Rheumatol 1995 22: 2250 2250
Makarov S.S. et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA Proc Natl Acad Sci USA 1996 93: 402 402
Bresnihan B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Arthritis Rheum 1998 41: 2196 2196
Caron J.P. et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis Arthritis Rheum 1996 39: 1535 1535
Evans C.H., Robbins P.D. . Clinical trial to assess the safety, feasibility, and efficacy, of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis Hum Gene Ther 1996 7: 1261 1261
Todhunter R., Lust G. . Pathophysiology of synovitis: Clinical signs and examination in horses The Compendium 1990 12: 979 979
McIlwraith C.W. . General pathobiology of the joint and response to injury McIlwraith CW, Trotter GW (eds); Joint Disease in the Horse Saunders Company 1996 pp 40–69
Pillemer S.R. et al. Meaningful improvement criteria sets in a rheumatoid arthritis clinical trial. MIRA Trial Group. Minocycline in Rheumatoid Arthritis Arthritis Rheum 1997 40: 419 419
Henderson B., Pettipher E.R. . The synovial lining cell: biology and pathobiology Semin Arthritis Rheum 1985 15: 1 1
Pelletier J. et al. Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis Arthritis Rheum 1985 28: 554 554
Hardy S. et al. Construction of adenovirus vectors through Cre-lox recombination J Virol 1997 71: 1842 1842
Ekman L. et al. Volume of the synovia in certain joint vacities in the horse Acta Vet Scand 1981 22: 23 23
Frisbie D.D. et al. The effects of triamcinolone acetate on an in vivo equine osteochondral fragment exercise model Equine Vet J 1997 29: 349 349
Frisbie D.D. et al. The effects of triamcinolone acetate on an in vivo equine osteochondral fragment exercise model
Anonymous. Definition and classification of lameness. In: Guide for Veterinary Service and Judging of Equestrian Events. Lexington: AAEP; 1991, p 19 Am J Vet Res 1997 58: 1132 1132
Frisbie D.D. et al. The assessment of chondrocyte proteoglycan metabolism using molecular sieve column chromatography as compared to three commonly utilized techniques Osteoarthr Cartilage 1998 6: 137 137
Frisbie D.D. et al. The assessment of chondrocyte proteoglycan metabolism using molecular sieve column chromatography as compared to three commonly utilized techniques
Frisbie D.D. et al. The assessment of chondrocyte proteoglycan metabolism using molecular sieve column chromatography as compared to three commonly utilized techniques
Acknowledgements
This work was supported by the American Association of Equine Practitioners; College Research Council, Colorado State University; and the Southern California Equine Foundation. The authors would like to acknowledge Dr Rick D Howard for kindly providing phagemid containing the EqIL-1Ra gene and Heather Colhoun, Emily Sandler, Jennifer Goodnight, and the Veterinary Teaching Hospital's Volunteer program for technical assistance, making this work possible.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frisbie, D., Ghivizzani, S., Robbins, P. et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 9, 12–20 (2002). https://doi.org/10.1038/sj.gt.3301608
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301608
Keywords
This article is cited by
-
A pilot study to determine the optimal dose of scAAVIL-1ra in a large animal model of post-traumatic osteoarthritis
Gene Therapy (2023)
-
A detailed macroscopic scoring system for experimental post-traumatic Osteoarthritis in the equine middle carpal joint
BMC Research Notes (2022)
-
Use of allogeneic freeze-dried conditioned serum for the prevention of degradation in cartilage exposed to IL-1ß
BMC Veterinary Research (2022)
-
Effects of oral treatment with chondroitin sulfate and glucosamine in an experimental model of metacarpophalangeal osteoarthritis in horses
BMC Veterinary Research (2022)
-
Genetic Therapy in Veterinary Medicine
BioNanoScience (2022)